Press Releases and News

A study published in the scientific journal PLOS ONE shows a strong correlation between impaired sensitivity on low frequencies and foot ulcers. Behind the study are five prominent researchers from Lund University and Skåne University Hospital in Malmö.

On 28 and 29 November 2018, the European Innovation Council (EIC) and Medtronic, a leader in the world of medical technology, gathered 20 companies to discuss the transformation of healthcare and promote business partnerships. VibroSense shared its solutions for early detection and diagnosis of nerve injuries in hand and foot (peripheral sensory neuropathy) caused by diabetes or by chemotherapy treatment of cancer.

Preliminary results from studies conducted in collaboration with VibroSense Dynamics AB (VibroSense) research network indicate that the company's instruments and technology have a high potential for detecting early neurological changes in diabetes and the treatment of cancer with chemotherapy. The company's product thus takes an important step to become part of the therapy in these areas.

For the first time ever, it has been shown that improved HbA1c (long-term blood sugar) is linked with improved tactile perception of feet in diabetic patients. The discovery was made in a study to evaluate the Multi-Frequency Vibrometry method and the VibroSense Meter® instrument. The result is reported by Dr. Eero Lindholm in a poster presentation at the EASD Diabetes Congress in Berlin on October 1-5, 2018. VibroSense Dynamics participates as exhibitor at stand 4J05.

The senior specialist at Skåne University Hospital, Dr. Eero Lindholm, will present study results showing that it may be possible to reverse nerve damage in feet caused by diabetes by improved metabolic control. VibroSense Dynamics participates as an exhibitor at EASD in Hall 4 at booth 4J05.

VibroSense Dynamics (VibroSense) has received a CE registration certificate of the company's new product VibroSense Meter II, by the Swedish Medicines Agency. The product is thus CE-marked and meets all requirements for sale, as a Class I medical device, within the EU. The instrument can also be sold in all other European countries harmonized with the EU regulations for CE marking of medical devices.

A study, published in the scientific journal PLOS ONE, reveals that 18 percent of examined children in Skåne, South of Sweden, with type 1 diabetes show initial signs of nerve damages in the feet, Diabetic Peripheral Neuropathy (DPN). The study also found that children, who used insulin pump instead of the insulin pen, had a lower degree of early signs of peripheral neuropathy.

The previously communicated study at the clinic of Oncology, at Skåne University Hospital, has now been granted an ethical approval. The purpose of the study is to investigate the extent to which VibroSense Meter can be used to detect nerve damage (neuropathy) that occurs in the treatment of colorectal cancer with Oxaliplatin. 30 patients will be included in the study and data collection is expected to be completed in November 2018. In an extension, the goal is to develop personalized treatment, aided by the company's product VibroSense Meter, to reduce or prevent nerve damage caused by chemotherapy.